Skip to main content
. 2012 Jul 31;20(11):2031–2042. doi: 10.1038/mt.2012.153

Figure 3.

Figure 3

Impact of AAVrh10-mGALC administration on growth, lifespan, and grip strength. (a) Weight maintenance of icv-ic-iv (n = 14) and icv-ic-iv-iv-treated affected mice (n = 10) are compared to untreated affected mice (n = 7) and wild-type mice (n = 5). (b) Survival rates of iv, ivc-ic, and icv-ic-iv-treated mice are compared to untreated affected mice. While iv-injected mice had modest increase in lifespan, the icv-ic and icv-ic-iv-injected mice had dramatic increases in lifespan. (c) Effect of an extra iv administration of AAVrh10-mGALC is compared to icv-ic-iv treatment alone. Note that some of the mice receiving the second iv injection lived shorter than icv-ic-iv-treated mice while some others had much extended lifespan. (d) The average lifespan of the mice treated with different viral administration strategies are compared to average lifespan of the untreated twitcher (twi) mice (untreated: n = 9, iv-treated: n = 10, icv-ic-treated: n = 10, icv-ic-iv-treated: n = 15, icv-ic-iv-iv-treated: n = 7). All treatment strategies resulted in a significant increase in life span of the treated mice compared to untreated twi mice (iv: P < 0.0001, icv-ic: P < 0.001, icv-ic-iv: P < 0.0001, icv-ic-iv-iv: P < 0.05). GALC, galactocerebrosidase.